283 related articles for article (PubMed ID: 32223515)
1. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Agents for the Treatment of Vasodilatory Shock.
Knotzer H; Poidinger B; Kleinsasser A
Curr Pharm Des; 2019; 25(19):2133-2139. PubMed ID: 31272348
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II in septic shock.
Jadhav AP; Sadaka FG
Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
[TBL] [Abstract][Full Text] [Related]
4. The pharmacotherapeutic options in patients with catecholamine-resistant vasodilatory shock.
Albertson TE; Chenoweth JA; Lewis JC; Pugashetti JV; Sandrock CE; Morrissey BM
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):959-976. PubMed ID: 35920615
[TBL] [Abstract][Full Text] [Related]
5. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
[TBL] [Abstract][Full Text] [Related]
6. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis.
McIntyre WF; Um KJ; Alhazzani W; Lengyel AP; Hajjar L; Gordon AC; Lamontagne F; Healey JS; Whitlock RP; Belley-Côté EP
JAMA; 2018 May; 319(18):1889-1900. PubMed ID: 29801010
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin in Vasodilatory Shock.
Ukor IF; Walley KR
Crit Care Clin; 2019 Apr; 35(2):247-261. PubMed ID: 30784607
[TBL] [Abstract][Full Text] [Related]
8. Vasodilatory shock in the ICU and the role of angiotensin II.
Wakefield BJ; Sacha GL; Khanna AK
Curr Opin Crit Care; 2018 Aug; 24(4):277-285. PubMed ID: 29877879
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Vasopressin as First-Line Treatment of Distributive and Hemorrhagic Shock States.
Haan BJ; Cadiz ML; Natavio AM
Ann Pharmacother; 2020 Mar; 54(3):213-218. PubMed ID: 31625395
[No Abstract] [Full Text] [Related]
10. Vasopressor therapy in critically ill patients with shock.
Russell JA
Intensive Care Med; 2019 Nov; 45(11):1503-1517. PubMed ID: 31646370
[TBL] [Abstract][Full Text] [Related]
11. Does the Addition of Vasopressin to Catecholamine Vasopressors Affect Outcomes in Patients With Distributive Shock?
Roumpf SK; Hunter BR
Ann Emerg Med; 2019 Jul; 74(1):153-155. PubMed ID: 30446352
[No Abstract] [Full Text] [Related]
12. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock.
Tsuneyoshi I; Yamada H; Kakihana Y; Nakamura M; Nakano Y; Boyle WA
Crit Care Med; 2001 Mar; 29(3):487-93. PubMed ID: 11373409
[TBL] [Abstract][Full Text] [Related]
13. [Indications of vasopressin in the management of septic shock].
Delmas A; Leone M; Rousseau S; Albanèse J; Martin C
Ann Fr Anesth Reanim; 2003 Jul; 22(7):600-8. PubMed ID: 12946492
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in perioperative anesthetic management update on the role of vasopressin and its effects on outcomes.
Udeh CI; Diaz-Gómez JL; Anthony D; Satyapriya A; Perez-Protto S; Hata JS
Curr Pharm Des; 2012; 18(38):6308-13. PubMed ID: 22762470
[TBL] [Abstract][Full Text] [Related]
15. Vasopressor Therapy in the Intensive Care Unit.
Russell JA; Gordon AC; Williams MD; Boyd JH; Walley KR; Kissoon N
Semin Respir Crit Care Med; 2021 Feb; 42(1):59-77. PubMed ID: 32820475
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II in Vasodilatory Shock.
Wakefield BJ; Busse LW; Khanna AK
Crit Care Clin; 2019 Apr; 35(2):229-245. PubMed ID: 30784606
[TBL] [Abstract][Full Text] [Related]
17. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.
Abril MK; Khanna AK; Kroll S; McNamara C; Handisides D; Busse LW
J Crit Care; 2019 Apr; 50():188-194. PubMed ID: 30553989
[TBL] [Abstract][Full Text] [Related]
18. Role of angiotensin II in treatment of refractory distributive shock.
Rodriguez R; Fernandez EM
Am J Health Syst Pharm; 2019 Jan; 76(2):101-107. PubMed ID: 31361800
[TBL] [Abstract][Full Text] [Related]
19. Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.
Rodriguez R; Cucci M; Kane S; Fernandez E; Benken S
J Intensive Care Med; 2020 Apr; 35(4):327-337. PubMed ID: 30563433
[TBL] [Abstract][Full Text] [Related]
20. The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock.
Saad AF; Maybauer MO
J Crit Care; 2017 Aug; 40():41-45. PubMed ID: 28319910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
